Hemoglobin C

Hemoglobin C. It is an abnormal hemoglobin variant caused by a specific point mutation in the beta-globin gene. This variant is most commonly found in populations with ancestry from West Africa. While often asymptomatic, it can cause a mild hemolytic anemia when inherited in a homozygous state or compound heterozygosity with other variants like Hemoglobin S.

Structure and genetics

The molecular basis of Hemoglobin C is a single nucleotide substitution in the HBB gene on chromosome 11. This mutation results in the replacement of glutamic acid with lysine at the sixth position of the beta-globin chain. The altered amino acid sequence decreases the solubility of the hemoglobin molecule within red blood cells. This biochemical change promotes the formation of intracellular crystals, particularly under conditions of reduced oxygen tension. The inheritance pattern is autosomal recessive, meaning two copies of the variant gene are typically required for full clinical expression. The structural abnormality contrasts with that of Hemoglobin S, which involves a different substitution at the same codon. Research into this variant has contributed significantly to the field of molecular medicine.

Clinical significance

Individuals homozygous for Hemoglobin C, a condition sometimes called Hemoglobin C disease, typically exhibit a mild, chronic hemolytic anemia. Common clinical features include splenomegaly and occasional episodes of jaundice. The presence of intracellular crystals can make red blood cells more rigid, though they do not sickle like those containing Hemoglobin S. The compound heterozygous state with Hemoglobin S, known as Hemoglobin SC disease, produces a clinically significant condition that can resemble a milder form of sickle cell disease. Complications in such cases may include retinopathy, avascular necrosis of the femoral head, and increased risk for bacterial infections due to functional asplenia. Unlike sickle cell anemia, painful vaso-occlusive crises are less frequent and severe. The interaction with other variants like Hemoglobin E or beta-thalassemia can also modify the clinical presentation.

Epidemiology

Hemoglobin C has a high frequency in certain regions of West Africa, particularly in Burkina Faso, northern Ghana, and southern Mali. Its prevalence is estimated to be as high as 25% in some local populations. The distribution suggests a possible selective advantage against severe malaria caused by Plasmodium falciparum, similar to the hypothesis for Hemoglobin S and Hemoglobin E. Due to the Atlantic slave trade, the gene was also dispersed to the Americas, the Caribbean, and parts of Southern Europe. In the United States, it is most commonly identified among individuals of African American descent. Population screening programs, such as those conducted by the World Health Organization, have helped map its global distribution. The variant is relatively rare in populations from Asia or Northern Europe.

Diagnosis and management

Diagnosis is typically made through laboratory techniques including hemoglobin electrophoresis and high-performance liquid chromatography. Peripheral blood smear examination often reveals characteristic target cells and, in some cases, intracellular crystals. Genetic testing can confirm mutations in the HBB gene. For homozygous Hemoglobin C disease, management is generally supportive and may include folic acid supplementation. Patients with Hemoglobin SC disease require more vigilant monitoring, often at specialized centers like the National Institutes of Health. Regular ophthalmologic evaluations are recommended to screen for proliferative retinopathy. Management strategies are informed by guidelines from bodies such as the American Society of Hematology. Vaccination against encapsulated bacteria like Streptococcus pneumoniae is crucial for those with functional asplenia. Unlike sickle cell disease, treatments like hydroxyurea are less commonly used.

History

Hemoglobin C was first identified in 1950 by the American researchers Harvey Itano and James Neel, working in the laboratory of Linus Pauling at the California Institute of Technology. Its discovery followed shortly after the landmark characterization of Hemoglobin S by Pauling and Itano, which established the concept of a "molecular disease." The initial cases were described in a family of African American descent. Further epidemiological studies by Anthony Allison and others explored its distribution in Africa and its relationship with malaria. The elucidation of its exact genetic mutation was a triumph of early molecular biology. The variant has been extensively studied at institutions like the National Heart, Lung, and Blood Institute. Its history is intertwined with the broader narrative of human genetics and the understanding of balanced polymorphism.

Category:Hemoglobinopathies Category:Genetic disorders